{
  "docId": "019dd923-622c-750b-8b9a-ad0811d3e80d",
  "docSlug": "dfcef8f28a20",
  "documentTitle": "Accelerate Diagnostics (AXDX)",
  "authorId": "61_White_Diamond_Research",
  "authorName": "White Diamond Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2019-09-16 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 27,
  "pageCount": 41,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide contrasts optimistic management commentary from 2018 with a more cautious tone in 2019.",
  "elementsJson": [
    "paragraph",
    "quote_block"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-ad0811d3e80d/27",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-ad0811d3e80d#slide-27",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Mehren seems optimistic and excited in the above quotes that LOS and mortality improvements for the Pheno system will be revealed in the Mayo/UCLA study. However, Mehren doesn’t sound so optimistic in the Q2 2019 call:",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a1-fde41e564a3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.135,
        "w": 0.77,
        "x": 0.118,
        "y": 0.093
      },
      "kind": "paragraph",
      "text": "What else can we infer from the cryptic management comments about the Mayo-UCLA study? In the past, Mehren told investors that he was optimistic the Pheno system would show an improvement in LOS. AXDX would always bring up the Mayo-UCLA study as a path to generating critical evidence for clinical (mortality, morbidity) and economic (length of stay, cost) benefits of the Pheno system.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17801d74-9de6-4c00-993b-5b58d1a4ebb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.77,
        "x": 0.118,
        "y": 0.633
      },
      "kind": "paragraph",
      "text": "Mehren seems optimistic and excited in the above quotes that LOS and mortality improvements for the Pheno system will be revealed in the Mayo/UCLA study. However, Mehren doesn't sound so optimistic in the Q2 2019 call:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9aa2bd57-b490-4e8f-82ef-5e73a2fc891f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.085,
        "w": 0.77,
        "x": 0.118,
        "y": 0.515
      },
      "kind": "quote",
      "text": "We believe the second of these studies to publish will be an independent multi-center government sponsored randomized prospective outcome study at Mayo Clinic, Rochester and UCLA. The studies endpoints include time to effective therapy, clinical improvement and cost.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d9b9aff-c9cc-4e92-847a-c25cbb5c6ae0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.77,
        "x": 0.118,
        "y": 0.765
      },
      "kind": "quote",
      "text": "I guess, I'll start off with the Mayo-UCLA trials coming up here in a couple of months. I believe a lot of investors' eyes are watching that now. .... should we expect to see a length of",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48b3ee58-69c3-43e2-afa7-b5fe80b1226e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.165,
        "w": 0.77,
        "x": 0.118,
        "y": 0.272
      },
      "kind": "quote",
      "text": "In late 2017 two institutions, the Mayo Clinic, Rochester and UCLA, secured IRB approval to conduct a randomized clinical trial investigating the efficacy and associate health economic outcomes of Pheno.... Regardless, the study is nearing completion, and we expect enrollment to finish in Q3 with early data soon after. If this study concludes as we hope it will demonstrate the improved outcome for these critically ill patients with positive impact on mortality and morbidity length of stay stewardship and cost. We can't wait.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d472eb6-0707-4096-9bd7-211bdcce7cd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "In late 2017 two institutions, the Mayo Clinic, Rochester and UCLA, secured IRB approval to conduct a randomized clinical trial investigating the efficacy and associate health economic outcomes of Pheno.... Regardless, the study is nearing completion, and we expect enrollment to finish in Q3 with early data soon after. If this study concludes as we hope it will demonstrate the improved outcome for these critically ill patients with positive impact on mortality and morbidity length of stay stewardship and cost. We can't wait. — Mehren (Q1 2018 Earnings Call)",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-78b4-70ad-b3a2-0222c940509c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "cb2d2553-3896-4c16-b1a9-19ef09ba5339",
      "evidence": "Contrasting optimistic 2018 quotes with cautious 2019 commentary",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}